Dr Reddy's Labs reported Q2FY18 revenue of INR 34,905 mn which grew 7.44% Q-o-Q but degrew 1.08% Y-o-Y. GST restocking and improved revenues from emerging markets led to healthy revenues in the quarter. Also US revenues is seeing some bottoming out in price erosion. The US revenues of the company have been stable in the quarter due to new product launches EBITDA stood at INR 6694 mn and has witnessed sharp surge in margin which stood at 18.8% in Q2 FY18 as against 9.7% in Q2 FY18. The lower R&D;...